BMS Newsroom |

6/19/13 2:02 am EDT
AstraZeneca and Bristol-Myers Squibb Announce Top Line Results for SAVOR-TIMI-53 Cardiovascular Outcomes Trial of Onglyza® (saxagliptin)
6/18/13 9:00 am EDT
Bristol-Myers Squibb Grants Help K-12 Educators Bring Science to Life and Help Students Explore Their Interests in the Sciences and Science-Based Careers
6/15/13 11:45 am EDT
Bristol-Myers Squibb and AbbVie Announce Progression-Free Survival Data from Phase 2 Open-Label Study of Investigational Agent Elotuzumab in Combination with Lenalidimide and Dexamethasone in Previously-Treated Multiple Myeloma
6/14/13 9:00 am EDT
AstraZeneca and Bristol-Myers Squibb to Present New Data at American Diabetes Association 73rd Scientific Sessions®
6/14/13 8:00 am EDT
Bristol-Myers Squibb and Simcere Enter Partnership to Co-Develop and Co-Commercialize Orencia® SC (abatacept) in China
6/12/13 1:11 pm EDT
AstraZeneca and Bristol-Myers Squibb Statement on Proposal by the American Diabetes Association for Independent Review of Incretin-Based Therapies
6/11/13 6:05 pm EDT
ORENCIA® (abatacept) Shows Comparable Efficacy to Humira® (adalimumab) in Year Two Data from Head-to-Head Study in Patients with Moderate to Severe Rheumatoid Arthritis
6/5/13 2:30 pm EDT
Bristol-Myers Squibb to Take Part in Goldman Sachs Global Healthcare Conference
6/4/13 9:03 am EDT
U.S. FDA Grants Priority Review to Bristol-Myers Squibb and AstraZeneca’s Metreleptin, an Investigational Agent for Treatment of Metabolic Disorders Associated with Rare Forms of Lipodystrophy
6/2/13 12:06 pm EDT
Bristol-Myers Squibb Announces Phase 1 Results from First Trial Combining Immune Checkpoint Inhibitors, Investigational Agent Nivolumab and Yervoy® (ipilimumab), in Patients with Advanced Melanoma

Business Wire NewsHQ℠